Clarivate acquires Bioinfogate

By The Science Advisory Board staff writers

August 4, 2021 -- Clarivate has acquired Bioinfogate, a life science research intelligence software developer.

The deal will help Clarivate fill a critical need for drug toxicity data and translational safety intelligence across every stage of drug research and development. The Bioinfogate Off-X portal is a safety intelligence tool designed to help pharmaceutical organizations identify toxicology and safety signals, mitigate safety liabilities, and de-risk early-stage assets. The translational safety and toxicity portals feature over 1.2 million safety alerts corresponding to over 23,000 drugs and biologics and more than 15,000 targets of pharmacological interest, according to the firms.

The Bioinfogate acquisition will strengthen Clarivate's ability to support customers across the entire drug development lifecycle, the company said. The terms of the deal were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.